Matthew J. Groysman

University of Arizona — United States

Medicine · Health Sciences

5h-index113citations19works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(14), Lung Cancer Research Studies(8), Lymphoma Diagnosis and Treatment(4), Colorectal Cancer Treatments and Studies(4), Tracheal and airway disorders(3)

Publications19 total

Comparison of margins and survival between transoral robotic surgery (TORS) and non-robotic endoscopic surgery for oropharyngeal cancer
American Journal of Otolaryngology·2023· 6 citedOpen Access
Supplementary Figures S1-S5 from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors
2023Open Access
Supplementary Tables S1-S2 from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors
2023Open Access
Data from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors
2023Open Access
Supplementary Figure Legend from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors
2023Open Access
Supplementary Figures S1-S5 from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors
2023Open Access
Supplementary References from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors
2023Open Access
Supplementary References from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors
2023Open Access
Supplementary Tables S1-S2 from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors
2023Open Access
Data from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors
2023Open Access
Supplementary Figure Legend from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors
2023Open Access
The impact of socioeconomic and geographic factors on access to transoral robotic/endoscopic surgery for early stage oropharyngeal malignancy
American Journal of Otolaryngology·2021· 10 cited
Association of Perioperative Complications with Vitamin D Levels in Major Head and Neck Surgery
The Laryngoscope·2021· 3 cited
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors
Oncotarget·2016· 22 citedOpen Access
Abstract 5451: Over-expression of NPM-ALK drives resistance to TKIs in ALK+ ALCL but is toxic upon drug withdrawal, permitting prolonged tumour control through discontinuous dosing
Cancer Research·2015
Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors
Cancer Research·2015· 45 citedOpen Access
Novel Resistance Mutations to ALK Tyrosine Kinase Inhibition Arising During Cell‐Culture Drug Selections in T‐Cell Lymphoma
The FASEB Journal·2015
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells
Biomarkers in Cancer·2015· 27 citedOpen Access
2013 Library Research Award Essay
UA Campus Repository (The University of Arizona)·2013

Frequent Co-authors

Amit Dipak Amin(15), Soumya Sundara Rajan(15), Jonathan H. Schatz(15), Praechompoo Pongtornpipat(14), Edgar Tapia(13), Winnie S. Liang(11), Tara L. Peters(11), Lori Cuyugan(11), Jonathan Adkins(11), Yves A. Lussier(11), Soham D. Puvvada(11), Lisa M. Rimsza(6), Lisa M. Rimsza(5), Audrey Baker(3), Shethal Bearelly(3), Steven J. Wang(2), Lingxiao Li(1), Vijay Gokhale(1), Mengdie Wang(1), Sun Yi(1)